SanoLiBio – SanoLiBio – Advancing Liquid Biopsy Technology

About Us

Our Story

SanoLibio is an internationally recognized biomedical technology innovator. Having understood that it is firstly technology that enables advancement, we have opened a new window with our proprietary automated cell separation platform into rare blood cell analysis which is seen as the next generation of liquid biopsy diagnostics potentially managing many health issues of our times, including cancer, myocardial infarction, diabetes and many more. Our unique rare cell enrichment platform called “Walderbach” is one of the very few worldwide to allow comprehensive ultra-rare cell enrichment and detection which is a crucial detail for the understanding of disease evolution and delineation that ultimately leads to better health care.

Latest News

Newsfeed

Announcement of publication in Medical Hypotheses Journal.

20.09.2021 This scientific article represents a hypothetical elaboration about potential use of systemic disease-associated circulating rare cells in comprehension for in-depth cytological analysis at the single cellular level. We denote …

Newsfeed

We’ve been named one of @hello tomorrow’s Deep Tech Pioneers!

23.09.2021 We’ve been named one of @hello tomorrow’s Deep Tech Pioneers! Come and meet us at the “Hello Tomorrow Global Summit 2021” along with 3,500 disruptive startups, investors, corporations and …

Newsfeed

Announcement of publication of our scientific article on Bone Marrow Damage Assessment by cell-based Liquid Biopsy

01.09.2021 Cyto-hematological investigations conducted by our group using the Walderbach platform in various clinical research tasks has leveraged the discovery of circulating cellular markers to indicate bone marrow damage. Imbalances …

Newsfeed

SanoLibio in Use

24.05.2022 – SanoLibio announces the commencement of a clinical trial conducted by its partner company Premise Biosystems Co., Ltd. (Thailand) in collaboration with Rama Thibodi Hospital in Bangkok for the …

Contact Us

Representation in Thailand

SanoLibio Co,. Ltd.

99/59 Moo 8 Racha Thewa Bang Phli
Samut Prakan 10540, Thailand

Management (Thailand)
Dr. Stefan Schreier
Usa Suteelaxnaporn
T: +66 838904716
E: info@sanolibio.com
Company registration:
Tax ID:0115562031174

Representation in Germany

SanoLiBio GmbH

Walpurgisstraße 4
81677 Munich, Germany

Management (Germany)
Dr. Stefan Schreier
Dipl.-BioIng. Timo Peter
T: +49 172 888 9848
E: info@sanolibio.com

Company registration:

Registration court: Munich
Registration number: HRB 233644
Tax ID: 143/177/81335
USt-ID: DE312531649
Content Responsibility: Stefan Schreier